Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Dec
04
Today In Oncology
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening
AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Survey Finds Global Embrace of Integrative Cancer Care
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo